At this year’s EASD conference, I had the chance to hold Tandem’s new 7-day infusion set, the SteadiSet, and perform a live demo. Tandem recently came on the podcast and walked us through the new infusion set and shared info on what else is coming down its pipeline. Seeing the set up close, though, made the differences even clearer: simpler application, longer-lasting, and clearly designed to make the lives of people with diabetes easier.

The SteadiSet is already cleared in the U.S. and expected to launch in 2026. When it arrives, it will work across Tandem’s lineup, including the t:slim X2, Tandem Mobi, and the company’s upcoming tubeless Mobi form factor.

One of the most immediate differences is in how you put on the new set. The applicator has two buttons on each side the user presses to place the set on the skin. It’s much easier than the current set which requires you to pinch, twist and pop on a set — typically requiring two hands to complete. This one makes the process feel less awkward and has less room for mess-ups. For people with limited dexterity, or anyone who just finds site changes fiddly, that design tweak could make a real difference.

Tandem also reworked the cannula. It measures 16 mm, is inserted at a 35-degree angle, and is reinforced with a coil to prevent kinking. Unlike traditional single-port designs, SteadiSet features four small insulin outlets. If one becomes blocked, delivery continues through the others — a safeguard intended to support longer wear and reduce occlusions.

The tubing connection has been updated as well. Instead of the familiar pinch-and-click, users now pop-on and twist to secure the line. It’s a minor adjustment, but one that just feels so much smoother, I must say.

This debut also fits into Tandem’s broader 2025–2026 rollout strategy. In addition to the SteadiSet, the company has updated its algorithm to Control-IQ+ (U.S. only for now), it’s developing an Android app, and expanding product availability internationally. Hardware projects are in the works too — including the a tubeless form factor for Mobi (expected next year) and the long-anticipated Sigi patch pump.

Longer wear-time for infusion sets is extremely welcomed as continuous glucose monitors (CGMs) push toward longer wear times of 15 days. Insulin pump changes every three days feels so repetitive, but changing that to two site changes for ever one CGM switch-out feels so right.

I hope we continue to see the trend move this direction. Aside from Tandem, Medtronic is the only other company who has a set lasting 7 days.

What questions do you have about the 7-day set? Drop them in the comments—and we’ll answer them as more details emerge.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.